Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Paul

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Epidemiologia E Prevenzione|December 1, 1990
[Avoidable deaths in the evaluation of the performance of health services. II. European Atlas of avoidable deaths: initial data and several reflections]P L Morosini, P Lauriola, E Magliola, et al.
Paraplegia|February 1, 1995
The effectiveness of the cervical halo: open versus closed ring. A preliminary reportF T Wetzel, N W Dunsieth, K R Kuhlengel, et al.
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|November 7, 2013
Field performance of derived generations of transgenic tobaccoP D Caligari, Y M Yapabandara, E M Paul, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 1997
Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibodyO Levy, G Dai, C Riedel, et al.
British Journal of Cancer|January 5, 2001
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patientsM M Malingré, J H Beijnen, H Rosing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918C M F Kruijtzer, J H Beijnen, H Rosing, et al.
Anti-Cancer Drugs|November 26, 1999
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinA Sparreboom, A S Planting, R C Jewell, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2004
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumorsA S T Planting, P Sonneveld, A van der Gaast, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Epidemiologia E Prevenzione|December 1, 1990
[Avoidable deaths in the evaluation of the performance of health services. II. European Atlas of avoidable deaths: initial data and several reflections]P L Morosini, P Lauriola, E Magliola, et al.
Paraplegia|February 1, 1995
The effectiveness of the cervical halo: open versus closed ring. A preliminary reportF T Wetzel, N W Dunsieth, K R Kuhlengel, et al.
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|November 7, 2013
Field performance of derived generations of transgenic tobaccoP D Caligari, Y M Yapabandara, E M Paul, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 1997
Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibodyO Levy, G Dai, C Riedel, et al.
British Journal of Cancer|January 5, 2001
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patientsM M Malingré, J H Beijnen, H Rosing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918C M F Kruijtzer, J H Beijnen, H Rosing, et al.
Anti-Cancer Drugs|November 26, 1999
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinA Sparreboom, A S Planting, R C Jewell, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2004
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumorsA S T Planting, P Sonneveld, A van der Gaast, et al.
Pageof 2